Olema appoints Jason O'Byrne as CFO ahead of pivotal OPERA-01 data readout

On August 13, 2026, Olema Pharmaceuticals, Inc. (the “Company”) announced the appointment of Jason O’Byrne as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, which was approved by the Board of Directors of the Company (the “Board”) on July 28, 2026 and effective as of August 11, 2026 (the “Effective Date”).

Pursuant to the Offer Letter, Mr. O’Byrne’s initial annualized base salary is $545,000. In addition, Mr. O’Byrne is eligible to receive an annual performance bonus with a target opportunity equal to 45% of his annual base salary. Mr. O’Byrne also received a sign-on bonus consisting of (i) $250,000, payable within 30 days following the Effective Date, and (ii) $100,000, payable within 30 days following the first anniversary of the Effective Date, in each case subject to certain service-based repayment obligations.

As provided in the Offer Letter, subject to approval by the Board, the Company will grant Mr. O’Byrne an option pursuant to the Company’s 2022 Inducement Plan (the “Plan”) to purchase 650,000 shares of the Company’s common stock (the “Option”). The Option will vest over four years, with 25% of the shares subject to the Option vesting on the first anniversary of the Effective Date and the remaining shares vesting monthly thereafter, subject to Mr. O’Byrne’s continued service to the Company through each applicable vesting date.

Pursuant to the Offer Letter, if the Company terminates Mr. O’Byrne’s employment without Cause (as defined in the Offer Letter) or Mr. O’Byrne resigns for Good Reason (as defined in the Offer Letter) within three months prior to or 18 months after a Change in Control (as defined in the Offer Letter), Mr. O’Byrne will be entitled to receive (a) a lump sum equal to 12 months of his then-current annual base salary plus his target bonus for the year in which the termination occurs; (b) a prorated annual bonus for the year in which the separation from service occurs, based on corporate performance for such year and the number of months of service during such year, as determined by the Board; (c) accelerated vesting of his then-outstanding unvested time-based equity awards; and (d) reimbursement of COBRA premiums for Mr. O’Byrne and his eligible dependents for up to 12 months.

On August 13, 2026, the Company issued a press release announcing the appointment of Mr. O’Byrne as the Company’s Chief Financial Officer.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer.

As we approach pivotal data from OPERA-01 and prepare for our first potential commercial launch, the breadth and depth of Jason’s expertise in corporate strategy, capital markets, business development, and financial management and operations will be essential as we continue Olema’s transformation into a fully integrated oncology company.

With a strong balance sheet and a series of important milestones ahead, I look forward to working with Sean and the executive team to help scale Olema through this next chapter and deliver durable benefit to patients and long-term value to shareholders.